# Intersection of cytoskeletal regulation with tumor cell metabolism

> **NIH NIH R01** · MAYO CLINIC ROCHESTER · 2024 · $429,079

## Abstract

SUMMARY
Pancreatic cancer (PDAC) is particularly lethal, due in part to a resistance to therapies and a high incidence of
metastasis. The overall goal of our research program is to define the molecular mechanisms regulating tumor
progression and metastasis of PDAC, thereby identifying new therapeutic strategies to improve patient survival.
This proposal focuses on an activator of the invasive cytoskeletal machinery, the proto-oncogene Vav1, which
is a GTP exchange factor and activator of the potent Rac/Cdc42 small GTPases that regulate actin dynamics.
Vav1 is aberrantly expressed in a subset of pancreatic tumors and correlates with a poor prognosis. Here we
have identified a novel role for Vav1 in the regulation of glutamine metabolism that we believe contributes to
cellular energy levels, thereby integrating a potent pro-invasive factor with an essential metabolic axis in PDAC.
Vav1 promotes the conversion of glutamine to glutamate via the enzyme glutaminase (GLS1). Further, we have
identified novel mechanisms by which the glutamine/glutamate axis contributes to tumor progression and
metastasis through both localized energy production and through paracrine signaling by both glutamate and
inflammatory cytokines. Our substantial preliminary data support the hypothesis for this proposal that ectopic
expression of the Rac/Cdc42 exchange factor Vav1 regulates glutamine metabolism to link nutrient status to
actin dynamics, invasion, and proliferation. Using a combination of cell biology, live cell fluorescence microscopy,
biochemistry, and in vivo models, we will test this hypothesis by investigating how Vav1 amplifies glutamine
catabolism (Aim 1), and how glutamate production drives tumor progression and metastasis in pancreatic tumor
cells (Aim 2). Successful completion of this research will provide fundamental mechanistic advances in our
understanding of the metabolic dependencies of PDAC, identify therapeutic vulnerabilities for patients with Vav1-
positive tumors, and establish novel links between cytoskeletal signaling and glutamine metabolism.

## Key facts

- **NIH application ID:** 10996553
- **Project number:** 1R01CA294653-01
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** MARK A. MC NIVEN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $429,079
- **Award type:** 1
- **Project period:** 2024-09-01 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10996553

## Citation

> US National Institutes of Health, RePORTER application 10996553, Intersection of cytoskeletal regulation with tumor cell metabolism (1R01CA294653-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10996553. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*